Nelivaptan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nelivaptan
Nelivaptan.png
Clinical data
Routes of
administration
Oral
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.210.987
Chemical and physical data
Formula C30H32ClN3O8S
Molar mass 630.11 g/mol
 NYesY (what is this?)  (verify)

Nelivaptan (INN)[1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]

See also[edit]

References[edit]

  1. ^ World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4): 341. 
  2. ^ Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. PMC 122955Freely accessible. PMID 11959912. doi:10.1073/pnas.092012099. 
  3. ^ Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS Drug Reviews. 11 (1): 53–68. PMID 15867952. doi:10.1111/j.1527-3458.2005.tb00035.x. 
  4. ^ "Second-quarter 2008 results" (PDF). Press Release. Sanofi-Aventis. 2008-07-31. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist). 

External links[edit]